Pasireotide for the treatment of acromegaly

Correlations between forced oscillation technique parameters and pulmonary densitovolumetry values in patients with acromegaly

(2015) G.B. Camilo et al.   BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH

A paradigm shift in the medical treatment of acromegaly: from a ‘trial and error’ to a personalized therapeutic decision-making process

(2015) Mônica R. Gadelha   CLINICAL ENDOCRINOLOGY

ACROSCORE: a new and simple tool for the diagnosis of acromegaly, a rare and underdiagnosed disease

(2015) Nunzia Prencipe et al.   CLINICAL ENDOCRINOLOGY

Failure to achieve disease control in acromegaly: cause analysis by a registry-based survey

(2015) C. Schofl et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Low Frequency of Cardiomyopathy Using Cardiac Magnetic Resonance Imaging in an Acromegaly Contemporary Cohort

(2015) Cintia Marques dos Santos Silva et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Early Lung Function Abnormalities in Acromegaly

(2015) A. Benfante et al.   LUNG

The incidence and prevalence of acromegaly, a nationwide study from 1955 through 2013

(2015) Gudrun Thuridur Hoskuldsdottir et al.   Pituitary

Prevalence of thyroid diseases in patients with acromegaly: experience of a Brazilian center

(2014) Helena Bandeira de Melo Paiva Uchoa et al.   Arquivos Brasileiros de Endocrinologia e Metabologia

Pharmacokinetics and Safety of Subcutaneous Pasireotide and Intramuscular Pasireotide Long-acting Release in Chinese Male Healthy Volunteers: A Phase I, Single-center, Open-label, Randomized Study

(2014) Xia Chen et al.   CLINICAL THERAPEUTICS

The incidence rate of pituitary adenomas in western Sweden for the period 2001–2011

(2014) Axel Tjörnstrand et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors

(2014) Andrea Giustina et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Long-Term Efficacy and Safety of Pegvisomant in Combination With Long-Acting Somatostatin Analogs in Acromegaly

(2014) S. J. C. M. M. Neggers et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Acromegaly: An Endocrine Society Clinical Practice Guideline

(2014) Laurence Katznelson et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study

(2014) A. Colao et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: A randomized, multicenter, open-label, phase I study

(2014) Stephan Petersenn et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The prevalence and associated factors of colorectal neoplasms in acromegaly: a single center based study

(2014) Masaaki Yamamoto et al.   Pituitary

Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study

(2014) Michael Sheppard et al.   Pituitary

Benign and Malignant Nodular Thyroid Disease in Acromegaly. Is a Routine Thyroid Ultrasound Evaluation Advisable?

(2014) Jordi L. Reverter et al.   PLoS One

Acromegaly and bone disease

(2014) Jeremy R. Anthony et al.   Current Opinion in Endocrinology Diabetes and Obesity

Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial

(2014) Mônica R Gadelha et al.   Lancet Diabetes & Endocrinology

Assessment of the absorption, metabolism and excretion of [14C]pasireotide in healthy volunteers using accelerator mass spectrometry

(2013) T.-H. Lin et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Functional evaluation of the joints in acromegalic patients and associated factors

(2013) Leandro Lemgruber Kropf et al.   CLINICAL RHEUMATOLOGY

Management of hyperglycemia associated with pasireotide (SOM230): Healthy volunteer study

(2013) Astrid Breitschaft et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern

(2013) Leandro Kasuki et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Somatostatin receptors: From signaling to clinical practice

(2013) Marily Theodoropoulou et al.   FRONTIERS IN NEUROENDOCRINOLOGY

Hyperglycemia Associated With Pasireotide: Results From a Mechanistic Study in Healthy Volunteers

(2013) Robert R. Henry et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of subcutaneous pasireotide on cardiac repolarization in healthy volunteers: A single-center, phase I, randomized, four-way crossover study

(2013) Astrid Breitschaft et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients

(2013) Orsalia Alexopoulou et al.   Pituitary

Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations

(2013) Annamaria Colao et al.   Pituitary

Management of hyperglycaemia in Cushing's disease: Experts’ proposals on the use of pasireotide

(2012) Y. Reznik et al.   DIABETES & METABOLISM

AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression

(2012) Leandro Kasuki et al.   ENDOCRINE-RELATED CANCER

Vertebral Fracture Assessment in Acromegaly

(2012) Miguel Madeira et al.   JOURNAL OF CLINICAL DENSITOMETRY

Long-Term Safety of Pegvisomant in Patients with Acromegaly: Comprehensive Review of 1288 Subjects in ACROSTUDY

(2012) A. J. van der Lely et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effect of Hepatic Impairment on the Pharmacokinetics of Pasireotide (SOM230): Results From a Multicenter Phase I Study

(2012) Yves Horsmans et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Elevated incidence of sleep apnoea in acromegaly—correlation to disease activity

(2012) J. Roemmler et al.   Sleep and Breathing

Novel pathway for somatostatin analogs in patients with acromegaly

(2012) Mônica R. Gadelha et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers

(2012) Georg Golor et al.   Drug Design Development and Therapy

Recomendações do Departamento de Neuroendocrinologia da Sociedade Brasileira de Endocrinologia e Metabologia para o diagnóstico e tratamento da acromegalia no Brasil

(2011) Leonardo Vieira Neto et al.   Arquivos Brasileiros de Endocrinologia e Metabologia

Aortic root ectasia in patients with acromegaly: experience at a single center

(2011) Alessandra Ferri Casini et al.   CLINICAL ENDOCRINOLOGY

Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study

(2011) Annamaria Colao et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone

(2010) Aart-Jan van der Lely et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Pasireotide (SOM230) Demonstrates Efficacy and Safety in Patients with Acromegaly: A Randomized, Multicenter, Phase II Trial

(2010) S. Petersenn et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly

(2009) Peter J. Trainer et al.   CLINICAL ENDOCRINOLOGY

Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed

(2009) Tirissa J. Reid et al.   CLINICAL ENDOCRINOLOGY

Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK)

(2009) Alberto Fernandez et al.   CLINICAL ENDOCRINOLOGY

Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients

(2009) SJCMM Neggers et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Expression Analysis of Dopamine Receptor Subtypes in Normal Human Pituitaries, Nonfunctioning Pituitary Adenomas and Somatotropinomas, and the Association between Dopamine and Somatostatin Receptors with Clinical Response to Octreotide-LAR in Acromegaly

(2009) Leonardo Vieira Neto et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Avaliação do metabolismo da glicose em pacientes acromegálicos antes e após tratamento com octreotide LAR

(2008) Lívia L. Correa et al.   Arquivos Brasileiros de Endocrinologia e Metabologia

Octreotide LARvs.surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study

(2008) Annamaria Colao et al.   CLINICAL ENDOCRINOLOGY

A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly

(2008) I M Holdaway et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Prevalence of sleep apnea and metabolic abnormalities in patients with acromegaly and analysis of cephalometric parameters by magnetic resonance imaging.

(2008) Flávia R B van Haute et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Quantitative analysis of somatostatin receptor subtypes (1–5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR

(2008) Giselle F Taboada et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

High prevalence of arthropathy, according to the definitions of radiological and clinical osteoarthritis, in patients with long-term cure of acromegaly: a case–control study

(2008) M J E Wassenaar et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Mortality in Acromegaly: A Metaanalysis

(2007) O. M. Dekkers et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Pasireotide (SOM230): Development, mechanism of action and potential applications

(2007) Herbert A. Schmid   MOLECULAR AND CELLULAR ENDOCRINOLOGY